Journal of Substance Abuse Treatment
Volume 38, Issue 1 , Pages 83-89 , January 2010

Preference for buprenorphine/naloxone and buprenorphine among patients receiving buprenorphine maintenance therapy in France: A prospective, multicenter study

  • Jean-Pierre Daulouède, M.D.

      Affiliations

    • Centre Bizia, Bayonne, France
    • Corresponding Author InformationCorresponding author. Centre Bizia, Bât. Zabal, Centre Hospitalier de la Côte Basque BP 08, 64100 Bayonne, France. Tel.: +33 05 59 44 31 00; fax: +33 05 59 52 08 16.
    • ,
  • Yves Caer, M.D.

      Affiliations

    • Hôpital Caremeau, Nîmes, France
    • ,
  • Pascal Galland, M.D.

      Affiliations

    • Centre Hospitalier, Béziers, France
    • ,
  • Pierre Villeger, M.D.

      Affiliations

    • Centre Hospitalier Esquirol, Limoges, France
    • ,
  • Emmanuel Brunelle, M.D.

      Affiliations

    • Centre Hospitalier, Lens, France
    • ,
  • Jérôme Bachellier, M.D.

      Affiliations

    • Centre Port Bretagne, Tours, France
    • ,
  • Jean-Michel Piquet, M.D.

      Affiliations

    • CSST Le Cèdre bleu, Lille, France
    • ,
  • Jean Harbonnier, M.D.

      Affiliations

    • Centre Hospitalier Lille, France
    • ,
  • Yves Leglise, M.D.

      Affiliations

    • UTTD Centre Charles Flahault CHU, Montpellier, France
    • ,
  • Pascal Courty, M.D., Ph.D.

      Affiliations

    • Centre Hospitalier, Clermont-Ferrand, France

Received 16 March 2009 ,Revised 2 June 2009 ,Accepted 17 July 2009.

References 

  1. Alho H, Sinclair D, Vuori E, Holopainen A. Abuse liability of buprenorphine–naloxone tablets in untreated IV drug users. Drug and Alcohol Dependence. 2007;88:75–78
  2. Auriacombe M, Franques-Reneric P, Daulouede JP, Tignol J. Buprenorphine prescribed by general practitioners—a safe means of increasing patient access to treatment?. In:  Waal H,  Haga E editor. Maintenance treatment of heroin addiction: Evidence at the crossroads. Oslo, Norway: Cappelen Academic Press; 2003;p. 190–204
  3. Bachert C, El Akkad T. Patient preferences and sensory comparisons of three intranasal corticosteroids for the treatment of allergic rhinitis. Annals of Allergy, Asthma & Immunology. 2002;89:292–297
  4. Barry DT, Moore BA, Pantalon MV, Chawarski MC, Sullivan LE, O'Connor PG, et al. Patient satisfaction with primary care office-based buprenorphine/naloxone treatment. Journal of General Internal Medicine. 2007;22:242–245
  5. Bell J, Shanahan M, Mutch C, Rea F, Ryan A, Batey R, et al. A randomized trial of effectiveness and cost-effectiveness of observed versus unobserved administration of buprenorphine-naloxone for heroin dependence. Addiction. 2007;102:1899–1907
  6. Carrieri MP, Amass L, Lucas GM, Vlahov D, Wodak A, Woody GE. Buprenorphine use: The international experience. Clinical Infectious Diseases. 2006;43:S197–S215
  7. Emmanuelli J, Desenclos JC. Harm reduction interventions, behaviours and associated health outcomes in France, 1996–2003. Addiction. 2005;100:1690–1700
  8. Fatseas M, Auriacombe M. Why buprenorphine is so successful in treating opiate addiction in France. Current Psychiatry Reports. 2007;9:358–364
  9. Fiellin DA, Moore BA, Sullivan LE, Becker WC, Pantalon MV, Chawarski MC, et al. Long-term treatment with buprenorphine/naloxone in primary care: Results at 2–5 years. American Journal on Addictions. 2008;17:116–120
  10. Fiellin DA, Pantalon MV, Chawarski MC, Moore BA, Sullivan LE, O'Connor PG, et al. Counseling plus buprenorphine–naloxone maintenance therapy for opioid dependence. New England Journal of Medicine. 2006;355:365–374
  11. Finch JW, Kamien JB, Amass L. Two-year experience with buprenorphine–naloxone (Suboxone) for maintenance treatment of opioid dependence within a private practice setting. Journal of Addictive Medicine. 2007;1:104–110
  12. Gueye PN, Megarbane B, Borron SW, Adnet F, Galliot-Guilley M, Ricordel I, et al. Trends in opiate and opioid poisonings in addicts in north-east Paris and suburbs, 1995–99. Addiction. 2002;97:1295–1304
  13. International Harm Reduction Association . Busy month for IHRA: October 2006. Available at: http://www.ihra.net/October20062006;Accessed on: April 8, 2008
  14. Mendelson J, Jones RT. Clinical and pharmacological evaluation of buprenorphine and naloxone combinations: Why the 4:1 ratio for treatment?. Drug and Alcohol Dependence. 2003;70:S29–S37
  15. Obadia Y, Perrin V, Feroni I, Vlahov D, Moatti JP. Injecting misuse of buprenorphine among French drug users. Addiction. 2001;96:267–272
  16. Simojoki K, Vorma H, Alho H. A retrospective evaluation of patients switched from buprenorphine (Subutex) to the buprenorphine/naloxone combination (Suboxone). Substance Abuse Treatment, Prevention, and Policy. 2008;3:
  17. Stoller KB, Bigelow GE, Walsh SL, Strain EC. Effects of buprenorphine/naloxone in opioid-dependent humans. Psychopharmacology (Berl). 2001;154:230–242
  18. Vidal-Trecan G, Varescon I, Nabet N, Boissonnas A. Intravenous use of prescribed sublingual buprenorphine tablets by drug users receiving maintenance therapy in France. Drug and Alcohol Dependence. 2003;69:175–181

PII: S0740-5472(09)00120-2

doi: 10.1016/j.jsat.2009.07.002

Journal of Substance Abuse Treatment
Volume 38, Issue 1 , Pages 83-89 , January 2010

Article Tools

* Image Usage & Resolution